SCHEDULE 13G/A: Actyus Private Equity Discloses 5.35% Stake in Elicio Therapeutics
Beneficial Ownership Report
Actyus Private Equity SGIIC, S.A. has filed an amended Schedule 13G, reporting a 5.35% beneficial ownership stake in Elicio Therapeutics, Inc. as of March 31, 2025.
Summary
- Actyus Private Equity SGIIC, S.A. (Actyus) has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Elicio Therapeutics, Inc.
- Actyus, acting as the management company for Azahar Private Capital, SCR, S.A. and NAVIS VB FUND I, reported beneficial ownership of 856,382 shares of Elicio Therapeutics' Common Stock.
- This ownership represents 5.35% of the class, calculated based on 15,996,976 shares outstanding as of May 9, 2025.
- Actyus holds sole voting power and sole dispositive power over all 856,382 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. The document is a factual disclosure of beneficial ownership, providing no explicit positive or negative performance indicators or forward-looking statements from the issuer.
Positives
- Actyus Private Equity SGIIC, S.A., an institutional investor, holds a significant 5.35% beneficial ownership stake in Elicio Therapeutics, Inc., indicating continued institutional interest in the company.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement (beneficial ownership threshold met/changed). |
| 05/09/2025 | Date as of which 15,996,976 shares of Common Stock outstanding were reported for percentage calculation. |
| 05/13/2025 | Date of the Company's Registration Statement on Form 10Q filing where shares outstanding were reported. |
| 05/14/2025 | Date of signing and filing of this Schedule 13G Amendment No. 1. |
Keywords
Elicio Therapeutics, Actyus Private Equity, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Private Equity, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.